Lord, Abbett & Co’s NovoCure NVCR Stock Holding History

Lord, Abbett & Co’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-13,562	Closed	-$3.01M	–	676
2021 Q2	$3.01M	Buy	+13,562	New	+$2.64M	0.01%	623

Other funds holding NVCR

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Lord, Abbett & Co's NVCR Position: Q3 2021 in Review

Lord, Abbett & Co sold out of NovoCure (NVCR) in Q3 2021, closing a stake of 13,562 shares — an estimated $3.01M sold.

Lord, Abbett & Co first reported a position in NVCR in Q2 2021 and held it in 1 quarter. The position peaked at $3.01M in Q2 2021. 317 funds tracked by Wall St. Rank hold NVCR as of Q3 2021.

Lord, Abbett & Co reported no remaining NovoCure position as of Q3 2021 after selling out during the quarter.
Lord, Abbett & Co sold 13,562 NovoCure shares in Q3 2021, an estimated $3.01M.
Lord, Abbett & Co first reported a position in NovoCure in Q2 2021 and held it in 1 quarter.
Lord, Abbett & Co's NovoCure position peaked at $3.01M in Q2 2021.
317 funds tracked by Wall St. Rank held NovoCure as of Q3 2021.

Based on Lord, Abbett & Co's 13F filing for Q3 2021, filed 9 Nov 2021.